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Abstract: The implementation of chemo- and bioinformatics tools is a crucial step in the design of
structure-based drugs, enabling the identification of more specific and effective molecules against
cancer without side effects. In this study, three new compounds were designed and synthesized
with suitable absorption, distribution, metabolism, excretion and toxicity (ADME-tox) properties and
high affinity for the G protein-coupled estrogen receptor (GPER) binding site by in silico methods,
which correlated with the growth inhibitory activity tested in a cluster of cancer cell lines. Dock-
ing and molecular dynamics (MD) simulations accompanied by a molecular mechanics/generalized
Born surface area (MMGBSA) approach yielded the binding modes and energetic features of the
proposed compounds on GPER. These in silico studies showed that the compounds reached the GPER
binding site, establishing interactions with a phenylalanine cluster (F206, F208 and F278) required for
GPER molecular recognition of its agonist and antagonist ligands. Finally, a 3-(4,5-dimethylthiazol-2-
yl)2,5-diphenyltetrazolium bromide (MTT) assay showed growth inhibitory activity of compounds 4,
5 and 7 in three different cancer cell lines—MIA Paca-2, RCC4-VA and Hep G2—at micromolar con-
centrations. These new molecules with specific chemical modifications of the GPER pharmacophore
open up the possibility of generating new compounds capable of reaching the GPER binding site
with potential growth inhibitory activities against nonconventional GPER cell models.
Keywords: GPER; docking; molecular dynamics simulations; Suzuki–Miyaura cross-coupling;
tetrahydroquinoline scaffold; antiproliferative
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1. Introduction
It is widely known that steroid hormones play a crucial role in carcinogenesis and
cancer progression [1]. Among this group of hormones, estrogen regulates several physio-
logical and disease processes in humans at a transcriptional level, known as the genomic
mechanism [2]. Additionally, there is a nongenomic level that involves rapid intracellu-
lar signaling, mediated through second messengers that are initiated by the activation
of membrane receptors, specifically G protein-coupled receptors (GPCRs) [3]. Recently,
a new estrogen membrane receptor was revealed as a pharmacological target in breast
cancer, encouraging researchers to find new ligands against breast cancer [3,4]. Originally,
this receptor was named as GPR30 but is now referred to as G protein-coupled estrogen
receptor (GPER) by the International Union of Basic and Clinical Pharmacology (IUPHAR;
www.iuphar.org/). GPER belongs to the superfamily of seven-transmembrane-spanning
GPCRs, which are the most important group of pharmacological targets in the pharmaceu-
tical market [5,6]. Specifically, GPER belongs to the class A rhodopsin-like GPCR family;
its primary transduction mechanism is led through coupling with Gαi/o proteins and its
secondary through the Gαs protein. GPER activates a network of transduction pathways,
such as formation of the epidermal growth factor receptor (EGFR), the mitogen-activated
protein kinases (MAPK), increment of the intracellular cyclic AMP (cAMP) and calcium
mobilization [7–9]. Dihydroquinoline derivative G1, the first synthetic agonist ligand
targeting GPER [10] that does not show affinity for estrogen receptors (ERα and ERβ),
contains a structural scaffold homologous to other GPER antagonists (G15 and G36), and
they differ only by the chemical moieties that could be responsible for their biological
responses as either agonists or antagonists [10–13].
As a promising agent for use in cancer therapy, GPER could be a biological target
in a wide range of cancer cells, producing positive results as quantified by their growth
inhibitory activity, including renal [14], liver [15] and pancreatic [16] cancers. It is important
to note that the biological activity of GPER is tissue-dependent as well as whether the
cells are healthy or cancerous and the ability of tissues to express GPER [17,18]. Recent
structural insights regarding the agonist/antagonist activities of GPER through in silico
methods to explain how and why the activation of this receptor occurs have been applied
to find new and more efficient ligands that target GPER [19,20]. In a previous study,
docking and molecular dynamics (MD) simulations were combined with a molecular
mechanics/generalized Born surface area (MMGBSA) approach to reveal the structural
and energetic basis of the molecular recognition between agonists or antagonists on the
GPER binding site. This study elucidated key residues of GPER involved in molecular
recognition, including a phenylalanine cluster (F206, F208 and F278) and a polar residue
(N310). The latter is considered to be a highly important residue involved in the activation
or inactivation mechanism of GPER [21].
In accordance with the knowledge of key amino acid residues involved in the molec-
ular recognition that dictates the binding mode of agonists and antagonists in the active
site of GPER, we focused our efforts on proposing strategic chemical modifications on the
pharmacophore that would improve molecular recognition through additional interactions
and, in turn, explore additional cavities that would increase selectivity and affinity at the
GPER binding site. First, we substituted the bromine atom with a phenyl ring, which
was in turn substituted with electron withdrawing (m-NO2) (compound 4) or electron
donating (m-OCH3) (compound 5) groups. The second chemical modification was to obtain
a molecule with a tert-butyl group off the piperidine ring (compound 7), seeking to increase
the hydrophobic environment that can establish interactions with the aforementioned
cluster of aromatic residues. Thus, we started with a G1 analog previously prepared by
our research group [22], which is subsequently referred to as G1-PABA. The chemical
synthesis of G1-PABA involved modification of the p-amino acetophenone of G1 using
p-aminobenzoic acid, which has shown inhibitory activity against breast cancer cells [22,23].
Once G1-PABA was synthetized, compounds 4, 5 and 7 were synthesized and tested in
renal, liver and pancreatic cancer cells. The results showed growth inhibitory activities (half
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maximal inhibitory concentration (IC50) values) less than 50 µM. In addition, the structural
and energetic properties of 4, 5 and 7 in the GPER binding site were explored by combining
docking and MD simulations with a MMGBSA approach, enabling us to correlate the
experimental and theoretical results.
2. Results and Discussion
2.1. Docking Calculations
To analyze the possible affinity and binding posture of the designed ligands in the
GPER binding site, docking studies were performed, and it was found that the designed
ligands were capable of reaching cavities in addition to those observed in previous re-
sults [20,21]. As we reported previously, the molecular recognition conducted by GPER
involves essential residues, mainly aromatic in nature, comprising a phenylalanine cluster
(F206, F208 and F278) and a polar residue (N310). Accordingly, in this study, in which
great chemical modifications of the chemical scaffold were explored (hindrance proper-
ties, electron donation and electron withdrawing as well as hydrophobic effects), either
agonist or antagonist GPER ligands examined in silico showed binding modes on GPER
that were equivalent to our previous findings [20,21]. Indeed, ligand 4 (m-NO2 phenyl
group) appeared to be in close contact with the phenylalanine cluster due to the ionic–π
interaction exerted by the electroattractant NO2 group facing the π electron density of
the phenyl groups in the phenylalanine cluster. This property was reflected in the better
binding energy of 4 (−8.46 Kcal/mol) compared to 5 (−8.36 Kcal/mol) due to the latter
having an electron-donating OCH3 group (Table 1). Ligand 7 showed a binding mode
in which the Boc (di-tert-butyl dicarbonate) moiety was in close contact with N310 (less
than 5 Å). The other important feature of 7 was that the orientation of its binding mode
overlapped with the binding mode of 5, sharing almost the same contacts with the residues
involved in the binding site (Table 1).
Table 1. The binding energies (−∆Gbinding in Kcal/mol) and interacting residues of G protein-coupled estrogen receptor
(GPER) towards the synthetized ligands yielded by docking analysis.
Ligand Binding Energy Nonbonded Interactions
4 −8.46 N44, H52, Q54 *, L59, L119, R122 *, F206
5 −8.36 Q53, Q54 *, G58, L59, H120*, F278 *, I279, H302 *, P303, G306, H307, N310
7 −8.21 E51, Q53 *, Q54, G58, L59, H120 *, F278 *, I279, H282 *, H302 *, P303, N310
* Residue forming H bond.
It is important to note that the pivotal residues (phenylalanine cluster and N310) were
not found at the same time to be involved in nonbonding interactions with the ligands
during the first docking recognition study, although it is well known that GPER contains
more than one binding site formed by residues of the same chemical nature as an orthosteric
binding site [20]. The resulting binding pose of the ligands obtained from the docking on
GPER (for an atomistic depiction please see the Figure S1 in Supplementary Material) were
employed as input coordinates for MD simulations combined with energetic calculations
using the MMGBSA approach. In addition, the ligands showed acceptable physicochemical
and toxicological–biological properties (absorption, distribution, metabolism, excretion
and toxicity (ADME-tox)) according to Lipinski’s rules, which are the parameters required
for new drug design (see Table 2). Toxicological–biological evaluations showed no effect
on any property analyzed.
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Table 2. Physicochemical and toxicological–biological properties of the ligands analyzed through
online servers. MW = molecular weight, HBD = hydrogen bond donor, HBA = hydrogen bond
acceptor, Mut = mutagenesis, Ter = teratogenicity, Irri = irritability, Rep = reproductive effects.
Ligand MW Log P HBD HBA Mut Ter Irri Rep
4 456.45 5.62 2 8 None None None None
5 441.48 5.71 2 6 None None None None
7 514.37 5.97 1 7 None None None None
2.2. Molecular Dynamics Simulations
2.2.1. Evaluation of the Equilibrium of Membrane-Embedded MD
GPER–Ligand Complexes
Docking studies demonstrated that the compounds studied established a different
map of contacts to those previously identified due to hindrance effects [20,21] involving
interactions with the phenylalanine cluster (F206, F208 and F278) and a polar residue
(N310) (data not shown). However, to provide more consistent information about the
prevalence of the interactions observed through docking calculations as well as to provide
conformational information, the GPER–ligand complexes were membrane-embedded and
submitted through 100 ns long MD simulations, accompanied by binding free energy
calculations using the MMGBSA approach to obtain a system with better physiological
conditions than rigid strategies.
Before performing any analysis of the structural and energetic values of the simulated
membrane-embedded GPER–ligand complexes, we evaluated the MD simulation time re-
quired to perform this analysis once the equilibration stages were reached (Figure 1). There-
fore, three geometrical values were evaluated to determine whether the systems reached
equilibrium: area per lipid of the 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphorylcholine
(POPC) membrane; root mean square deviation (RMSD) of heavy atoms; and the radius of
gyration (Rg) of the GPER with respect to the starting conformation. Figure 1A shows the
MD simulation time evolution of the area per lipid for the three GPER–ligand complexes. It
was observed that for the first 30 ns of each MD simulation, the area per lipid values were
high but then decreased and converged at 60 ns to values of 61.03 ± 0.26, 61.34 ± 0.30 and
60.76 ± 0.32 Å for GPER-4, GPER-5 and GPER-7, respectively. RMSD analysis showed that
the three GPER–ligand complexes reached equilibrium at similar MD simulation times (ap-
proximately 50 ns) with RMSD values of 2.6 ± 0.12, 2.2 ± 0.17 and 2.5 ± 0.11 Å for GPER-4,
GPER-5 and GPER-7, respectively (see Figure 1B). Similarly, the Rg analysis illustrated that
the three systems reached equilibrium at 60 ns with Rg values of 26.5 ± 0.1, 26.4 ± 0.13
and 26.5 ± 0.12 Å for GPER-4, GPER-5 and GPER-7, respectively (see Figure 1C). Based on
these observations, it was evident that the three systems reached equilibrium at 60 ns, from
which root mean square fluctuation (RMSF) calculations and subsequent analyses were
performed. The RMSF analysis over the equilibrated simulations (the last 40 ns of the MD
production runs) revealed that the molecular flexibility of the three systems were similar
(see Figure 1D). The loop (residues 20–50) that flanked the receptor binding site was the
region that exhibited the highest conformational mobility for the three systems, whereas
loop 5 (residues 245–251) exhibited the highest flexibility for GPER-7 only (see Figure 1D).
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Figure 1. Equilibrium propert es of GPER–ligand systems through molecular dyna ics (MD) simulations. (A Area per
lipid values; (B) root mean square dev ation (RMSD); (C) radius of gy ation (Rg); (D) root mean square fluctuation (RMSF)
for GPER-4 (red), GPER-5 (blue) and GPER-7 (black).
2.2.2. Clustering Analysis
Clustering analysis over the equilibrated time was carried out for the GPER-4, GPER-5
and GPER-7 complexes to detect all conformational states of each complex. Clustering
analysis using a cut-off of 2.0 Å demonstrated that GPER-4, GPER-5 and GPER-7 complexes
were characterized by one, three and five clusters of conformers, respectively, with 100%,
73% and 56% of the clusters of each GPER-ligand complex being represented by the first
cluster, respectively. This analysis allowed us to obtain the most populated conformation,
which was useful in evaluating the map of interactions between the ligands and GPER.
2.2.3. Principal Component Analysis (PCA)
The total fluctuation of the GPER-4, GPER-5 and GPER-7 complexes was evaluated
using Cartesian principal component analysis (cPCA) (see Methods). This analysis revealed
that the total motion of the GPER-4, GPER-5 and GPER-7 complexes was dispersed over
3375 eigenvectors; however, the total MD simulations were described by 15 eigenvectors.
Figure 2 shows the first 15 collective modes (Figure 2A) for the three systems and their
individual percentages (Figure 2B). The collective modes captured 69.5%, 69.4% and 75.3%
of the total motion for the GPER-4, GPER-5 and GPER-7 complexes, respectively. The
projection of GPER-4, GPER-5 and GPER-7 onto eigenvectors 1 and 2 (PC1 vs. PC2) showed
that the fluctuation of the three systems was co fined withi thes two eigenvectors.
However, GPER-7 covered a larg r region of phase pace along the PC1 and PC2 plane
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than GPER-4 and GPER-5, and this latter complex covered a larger region of phase space
along the PC1 plane than GPER-4. The clusters of stable states were more defined in GPER-
4 than GPER-7 and GPER-5. Quantification of the total flexibility among the different
protein–ligand complexes, shown in Figure 2C, was obtained by analyzing the trace of
the diagonalized covariance matrix of the backbone atomic positional fluctuations. Based
on this parameter, the values for GPER-7 (12.71 nm2), GPER-4 (9.35 nm2) and GPER-5
(9.94 nm2) revealed differences in conformational flexibility in the order of GPER-7 > GPER-
5 > GPER-4. This order was in line with the conformational complexity identified through
the cluster analysis.
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GPER-4 (red), GPER-5 (blue) and GPER-7 (black). (B) The percentage of each eigenvector from panel A. (C) Projection of the
motion in the phase space along the first and second eigenvectors (principal component (PC) 1 vs. PC2) for GPER-4 (red),
GPER-5 (blue) and GPER-7 (black).
2.2.4. Structural Analysis of the Empty and Bound GPER Systems
Structural details of a map of the interactions for the GPER–ligand complexes were
analyzed considering the most populated conformation obtained through cluster analysis
(Figure 3). A comparison of the map of interactions of the three complexes showed that 7
(Figure 3B) and 4 (Figure 3C) shared contact with five of the same residues: Gln53, Leu59,
Arg122, Met133 and Leu137. Ligands 7 and 5 also shared contacts with Gln53, Leu59,
Glu275, Arg122 and Gly58, and 5 and 4 shared contacts with Gln53, Leu59, Leu119, His120
and Arg122. However, only three residues (Gln53, Leu59 and Arg122) were shared by all
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three compounds, indicating that small modifications in the pharmacophore group can
modify the map of interactions.
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Overall, this analysis revealed that the three compounds were mostly stabilized by
hydrophobic residues. Residues belonging to the phenylalanine cluster (F206, F208 and
F278) were identified as important stabilizers of the complexes with GPER [20,21]. Among
the three complexes, only 4 (F206 and F208) and 5 (F278) were able to establish contact
with some members of this cluster. With respect to polar interactions, only 7 and 4 were
able to establish hydrogen bonds and salt bridges through their polar moieties at the GPER
binding site. Ligand 7 formed a hydrogen bond with Gln53 and a salt bridge with Arg122
through its carboxyl group (Figure 3B), whereas 4 was stabilized by two hydrogen bonds
through its carboxyl group with His120 and its NO2 group with Cys207 (Figure 3C). The
latter polar interaction has been reported to be responsible for inducing the activated
state [20]. Interestingly, the lack of a bromine (Br) atom in these compounds means that the
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polar interactions observed in G1 and G15 through Asn307 or Asn310, respectively [21],
were not present. Instead, these two residues appeared in GPER-7 and GPER-5, forming
polar interactions through backbone atoms.
2.2.5. Absolute Binding Free Energy Calculations
The absolute binding free energy (∆Gbind) was calculated to measure the energetic
contributions in terms of noncovalent energies at the binding site of the GPER-4, GPER-5
and GPER-7 complexes (see Methods). This analysis revealed that the ∆Gbind values for the
three GPER–ligand systems, considering the entropic component, were thermodynamically
favorable for all complexes (Table 3). The main energetic contribution to ∆Gbind was guided
by the nonpolar contributions (∆Enonpolar = ∆Evwd + ∆Gnpol,sol), whereas the polar contribu-
tions (∆Epolar = ∆Eele + ∆Gpol,sol) displayed a thermodynamically unfavorable performance
that contrasted with the binding process for the three complexes. Based on the entropic
values (Table 3), it was observed that the three complexes exhibited a significant conforma-
tional reduction upon complex formation, notably impacting the ∆Gbind value, suggesting
that this molecular recognition was guided through an unfavorable entropic component.
The GPER-4 system exhibited a more energetically favorable ∆Gbind than the GPER-7 and
GPER-5 complexes, suggesting that the NO2-containing compound established a more
energetic map of interactions into the GPER binding site than the other two compounds.
Table 3. Binding free energy components of bound GPER systems (in units of Kcal/mol): the polar (∆Epolar = ∆Eele +
∆Gele,sol) and nonpolar (∆Enonpolar = ∆Evwd + ∆Gnpol,sol) contributions. All the energies are averaged over 400 snapshots
at time intervals of 100 ps from the last 60 ns production runs and are in Kcal/mol (±standard deviation). Results were
obtained by MD computations.
System ∆Evdw ∆Eele ∆Gele,sol ∆Gnpol,sol ∆Epolar ∆Enonpolar ∆Gmm/gbsa TDS ∆Gbind
GPER-4 −51.66(2.9) 15.72 (4.2)
3.50
(0.10) −6.44 (0.22) 19.22 −58.10 −38.88 (4.0) −26.43 (1.4) −12.43
GPER-5 −47.3(2.78) 19.15 (3.0)
4.70
(0.45) −6.10 (0.20) 23.85 −53.40 −29.55 (3.2) −22.34 (2.6) −7.21
GPER-7 −41.73(2.5) −3.90 (0.3)
22.94
(0.3) −5.52 (0.10) 19.04 −47.25 −28.21 (2.5) −24.14 (1.3) −4.07
2.3. Antiproliferative Assays
GPER plays a pivotal role in triggering cancer development, and most studies in the
literature have focused on its overexpression in breast cancer. The current findings relate to
the properties of GPER, particularly that its activity depends specifically on the expression
tissue and the cognate ligands (either agonist or antagonist) that activate or inactivate it.
Thus, new possibilities have been generated in the evaluation of new compounds targeting
GPER in cancer cells, unlike classical models of activity evaluation [24–26]. However,
there are other types of cancer in which GPER is present, and it could be an interesting
biological target in some other cancers, such as renal [14], liver [15] and pancreatic [16].
The evaluation of growth inhibition of the synthetized compounds was conducted using
a 3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay in selected
cancer cell lines. RCC4-VA, RCC4-VHL, MIA Paca-2 and Hep G2 were used to investigate
the possible antiproliferative effects of these three compounds as these are diverse cancer
cells that all have GPER in common. As shown in Table 4, MIA Paca-2 was the most
sensitive cancer cell line to the compounds tested. In this cell line, all tested compounds
had an antiproliferative effect in a concentration-dependent manner. The most effective
ligand in the MIA Paca-2 cell line was 7, which has a Boc protecting group on the amine
of the piperidine ring of the pharmacophore of GPER (see Figure 4). In this cell line, the
expression pattern of estrogen receptors is known, and antiestrogen therapy is used to
block ER activity in order to treat the cancer [27,28].
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Table 4. Half maximal inhibitory concentration (IC50) values obtained for the ligands tested in the
cancer cell lines. Values >50 are displayed for information only; values are in µM range.
IC50
Ligand RCC4-VA RCC4-VHL MIA Paca-2 Hep G2
7 24.46 >50 14.78 >50
4 >50 >50 18.18 >50
5 39.29 >50 21.15 31.58
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The GPER signaling pathway was studied and it role i both hea thy and cancerous
processes were examined, particularly with egard t the very important role in the tumor
microenvironment for renal, liver and pancreatic cancers, which could be affected by the
synthetized compounds. Interestingly, only two compounds showed an effect in mediating
growth inhibition in the RCC4-VA cell line (7 and 5), but with higher concentrations
than those assayed in MIA Paca-2 cells (see Figure 5). In this cell line, it is important
to note that the trend of 4, which showed a non-dose-dependent behavior (evident at
6.3 µM concentration), might be due to intrinsic properties of the cell to adapt to increased
concentrations of the tested compounds. In this case, the cell could be increasing the
expression of proteins involved into externalize the drugs (e.g., P-glycoprotein (PGP)
ATPase) or another mechanism, which conferred to the cell the capability to not respond to
the treatments assayed. This correlated with the result yielded by 7 assayed at the highest
concentration, although the result was slightly lower than the previous concentration
(25 µM). This pharmacological phenomenon is named as a biphasic pattern and has been
observed for other cancer cells (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC456
0104/). In contrast, in the RCC4-VHL cell line, all compounds showed activity at the
concentrations assayed (data not shown). This result is promising due to the molecular
differences by which these cell lines are employed, noting that VHL/HIF deregulated
signaling and the distinctive molecular feature of RCC4-VA cells responsible for the high
rate of tumors characteristic of Von Hippel-Lindau syndrome [29,30]. Finally, in Hep G2
(human liver carcinoma) c lls, only compound 5 showe ctivity (Figure 6) with lmost the
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same concentration found for RCC4-VA. This result might unmask an axis that involves
the participation of GPER/HIF-1α/vascular endothelial growth factor (VEGF) as has been
reported elsewhere [31]. Additionally, all cell models tested have been implicated in
processes in which the participation of molecular mediators under hypoxic conditions are
initiated once GPER activation has occurred [32,33]. These findings suggest that GPER is a
potential pharmacological target to develop new therapeutic strategies for cancer.
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3. Materials and Methods
3.1. Docking, Physicochemical and ADME-Tox Properties Analysis
The potential interaction between the designed compounds and GPER was analyzed
using molecular docking studies. First, the two-dimensional (2D) chemical structures of
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the ligands were drawn with the ChemBioDraw Ultra 12.0 program [34]. The Z-matrices of
the structures were generated using the Gauss View 5.0 program [35] to assign the correct
interatomic distance and hydrogen types. This step was undertaken through energetic
and geometric minimization under an AM1 semiempirical method that employed the
quantum chemistry package Gaussian 09 [36]. The GPER three-dimensional (3D) model
previously generated and validated by our research group was used in the molecular
docking simulations [20]. These simulations were carried out using the AutoDock 4.2.6
software [37]. Polar hydrogen atoms were added to the polar atoms of the protein, and
Kollman charges were assigned. Gasteiger charges were assigned for ligands, and a grid-
based procedure was used to generate the affinity maps delimiting the protein binding site
with the following grid box parameters: XYZ of 60 Å3 over the Cα atom of the N310 residue
(focused procedure) with a grid spacing of 0.375 Å3. Scoring sampling used the Lamarckian
genetic algorithm considering the following as search parameters: a randomized initial
population of 100 individuals and a maximum number of energy evaluations of 1 ×
107 cycles. The ligand–receptor interactions were analyzed with PyMOL v0.99 graphical
viewer [38]. The physicochemical and ADME-tox properties were analyzed using the
Molinspiration server [39] and DataWarrior software [40], respectively.
3.2. Embedding of the GPER–Ligand Complexes into the Membrane
Orientation of the GPER-4, GPER-5 and GPER-7 complexes with respect to the
POPC membrane was performed using the Orientations of Proteins in Membranes (OPM)
server [41]. Rectangular pre-equilibrated POPC bilayers were built for each complex using
the membrane builder tool CHARMM [42] with dimensions 110.437 × 110.437 × 122.485
Å (xyz). GPER–ligand complexes were embedded into the POPC bilayer using the replace-
ment method in CHARMM [43,44]. POPC bilayers constituted approximately 314 POPC
phospholipids with 154 and 160 on the outer and the inner leaflets, respectively, and they
were solvated using the TIP3 water model and neutralized with an ionic strength of 0.15 M
by NaCl using the solvation and autoionize module [43].
3.3. MD Simulations of the Membrane-Embedded GPER–Ligand Complexes
The MD simulations were performed with pmemd.cuda AMBER 12 executable [45].
Topologies for the GPER–ligand complexes were built using the Leap module, employing
the ff99SB, Lipid11 and GAFF force fields [46,47]. These complexes were minimized and
equilibrated with the sander module through the following steps. The complexes were
energy minimized through 10,000 steps with position restraints on the receptor and lipids
to allow relaxation of the water molecules. Complexes were slowly heated under constant
temperature and constant volume (NVT) ensemble through two sequential runs from 0
to 300 K for 1 ns, maintaining the receptor atom and lipid restraints. Afterwards, a 1 ns
simulation under the NPT ensemble at 300 K and 1 bar pressure with the heavy atoms
restrained was carried out to equilibrate the system, followed by 1 ns of equilibration
with the fully unrestricted system. The equilibration runs were followed by 100 ns MD
simulations, which were run for each system without position restraints under periodic
boundary conditions (PBCs) using a NPT ensemble at 300 K and 1 bar pressure. The
electrostatic interactions were computed by the particle mesh Ewald (PME) method [48].
A 10 Å cut-off was used for the van der Waals interactions, and the SHAKE algorithm
was used to constrict the bonds between the heavy atoms and hydrogen atoms [49]. The
temperature was conserved using Langevin dynamics, and pressure was controlled using
a semi-isotropic constant surface tension to preserve a specific area per lipid. The pressure
was maintained at 1 bar, and the pressure coupling constant was set to 1 ps with a collision
frequency of 1 ps−1. The time step was set to 2 fs, and the coordinates were saved for
analysis every 1 ps.
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3.4. Analysis of MD Simulations
The RMSD and Rg were calculated only for the α-carbon atoms and the receptor,
respectively, after removing the overall translational and rotational motion. The area per
lipid was calculated using the following equation: area per lipid = (box X length × box Y
length)/number of phospholipids per layer. The most populated conformers, which are by
definition the most stabilized systems present in a physiological context, were obtained
through a RMSD conformational clustering analysis using the g_cluster command with the
GROMOS algorithm and a cut-off of 0.25 nm [50] to evaluate the conformational features
linked to the most stable GPER–ligand complexes. Images and structural representations
were prepared using PyMOL v0.99 [38].
3.5. Principal Component Analysis
Principal component analysis, the essential dynamics (ED) method [51] and the
g_covar and g_anaeig GROMACS 4.5.3 package utilities [52,53] were implemented to
predict the collective motion of atoms. The symmetric matrix was diagonalized to form a
covariance matrix, which was used to obtain a set of eigenvectors and eigenvalues. The
essential subspace relevant to the GPER–ligand systems was constructed by projecting the
PCA along the most significant eigenvectors.
3.6. Calculation of Absolute Binding Free Energies
The binding free energy was computed for the GPER–ligand complexes using the
MMGBSA method and the single trajectory approach [54–61]. To this end, the water
molecules and counterions were removed from the trajectory, and the energy computations
were performed by selecting 400 snapshots at time intervals of 100 ps from the last 40 ns of
the simulation run for each system. The binding free energy (∆Gbind) of each GPER–ligand
complex was calculated as follows:
∆Gbind = Gcomplex − Greceptor − Gligand (1)
= ∆EMM + ∆GGB + ∆GSA − T∆S (2)
where ∆EMM corresponds to the gas-phase interaction energy for the protein–ligand com-
plex, which includes the van der Waals (∆Evdw) and the electrostatic (∆Eele) interaction
energies; ∆GGB and ∆GSA are the electrostatic and nonpolar contributions to desolvation
upon ligand binding, respectively; and −T∆S is the entropy contribution, which is a result
of the structural changes in the degrees of freedom between the free and bound partners
forming the protein–ligand complex. Because −T∆S was considered in the computation of
the binding free energy calculations, the values we obtained using the MMGBSA approach
could be named as absolute binding free energies, ∆Gbind.
3.7. Calculation of Entropy Contributions
The entropy contribution was evaluated for each complex using the MMPBSA.py
module implemented in Amber 12. Due to the large memory required for this calculation,
only 20 snapshots were selected for each GPER–ligand complex at time intervals of 2 ns
from the last 40 ns of each simulation run.
3.8. Chemical Synthesis
All reagent-grade chemicals were obtained from commercial suppliers and were used
without further purification. Reactions were monitored by thin-layer chromatography
(TLC) on aluminum-backed sheets with silica gel 60 GF254 (HX805651) and a fluorescent in-
dicator (visualized with UV light of 254 nm). Flash chromatography was performed using
silica gel 60 (230–400 mesh). Melting points (mp) were determined on an Electrothermal IA
91000 apparatus (Electrothermal, Bibby Scientific, Staffordshire, ST15 OSA, UK) and were
uncorrected. 1H and 13C NMR spectra were obtained on a Varian Mercury 300 MHz spec-
trometer or a Bruker Avance III 750 MHz spectrometer using deuterated dimethyl sulfoxide
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(DMSO-d6) or deuterated chloroform (CDCl3) as the solvent and tetramethylsilane (TMS) as
the internal standard. Chemical shifts (δ) are reported in ppm downfield from the internal
standard, and coupling constants are reported in Hertz (Hz) (Supplementary Material).
Electrospray ionization high-resolution mass spectrometry positive mode (ESI-HRMS) was
performed with an Agilent 6545 QTOF LC/MS instrument (Agilent Technologies, Santa
Clara, CA, USA).
3.8.1. Synthesis of (3aS, 4R, 9bR)-4-(6-Bromobenzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-
3H-cyclopenta[c]quinoline-8-carboxylic acid, G1-PABA 1
G1-PABA (1) and the tert-butyl derivative (compound 7) were obtained following the
previous method reported by our research group [22,23].
3.8.2. Synthesis of (3aS, 4R, 9bR)-4-(6-(3-Nitrophenyl)benzo[d][1,3]dioxol-5-yl)-3a,4,5,9b-
tetrahydro-3H-cyclopenta[c]quinoline-8-carboxylic acid, 4
Compound 4 was obtained by following the previously reported method [62]. G1-
PABA (0.020 g, 0.048 mmol), m-nitro phenylboronic acid (0.0096 g, 0.057 mmol), PEG2000
(0.060 g, 0.10 mmol) and Pd(AcO)2 (0.004 g, 0.017 mmol) were added to a solution of K2CO3
(0.0266 g, 0.19 mmol) and MeOH/H2O (7 mL) in a 1:1 mixture with constant stirring (see
Scheme 1). The reaction mixture was heated to reflux at 70 ◦C for 5 h under N2 atmosphere.
The mixture was then enabled to cool to room temperature, and the resulting mixture
was extracted with EtOAc (3 × 25 mL). The organic phase was washed with distilled
water and brine, dried over anhydrous sodium sulfate (Na2SO4) and concentrated under
reduced pressure. The residue was purified by flash chromatography using a mixture of
hexane/EtOAc (7:3) as the eluent, affording 55% yield of compound 4 as a clay solid, Rf =
0.42 (hexane/EtOAc, 7:3), mp = 184–185 ◦C. HPLC purity = 97.19 %. 1H NMR (750 MHz,
CDCl3) δ 8.22 (d, 1H, 7.5 Hz, H-4′ ′), 8.14 (bs, 1H, H-2′ ′), 7.68 (d, 1H, J = 7.5 Hz, H-7), 7.67 (s,
1H, H-9), 7.60 (d, 1H, J = 7.5 Hz, H6′ ′), 7.57 (t, 1H, J = 7.5 Hz, H5′ ′), 7.26 (s, 1H, H-7′), 7.23
(s, 1H, H-4′), 6.68 (s, 1H, NH), 6.56 (d, 1H, J = 7.5 Hz, H-6), 6.06 and 6.05 (AB, 2H, H-2′),
5.88 (bm, 1H, H-1), 5.69 (bm, 1H, H-2), 4.29 (d, 1H, J = 3.7 Hz, H-4), 4.22 (d, 1H, J = 6.0 Hz,
H-9b), 2.67 (m, 1H, H-3a), 1.71 (m, 1H, H-3 down), 1.44 (m, 1H, H-3 up). 13C NMR (187.5
MHz, CDCl3) δ 167.9 (CO2H), 150.4 (C-7a’), 148.3 (C-3′’), 148.2 (C-3′), 146.9 (C-5a), 142.5
(C-1′ ′), 135.6 (C-6′ ′), 133.9 (C-2), 133.1 (C-6′), 132.6 (C-9), 132.0 (C-1), 130.6 (C-4′), 129.6
(C-5′ ′), 129.5 (C-2′ ′), 124.8 (C-7), 124.4 (C-4′ ′), 122.6 (C-9a), 119.4 (C-8), 115.3 (C-6), 110.4
(C-4′), 107.1 (C-7′), 101.8 (C-2′), 53.6 (C-4), 45.6 (C-9b), 39.0 (C-3a), 38.9 (C-3). HRMS (ESI)
calculated for ([C26H20N2O6] + H)+: 457.1400; found: 457.13824.
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Compound 5 was obtained through a Suzuki–Miyaura cross-coupling reaction [63]. A solution 
of K2CO3 (0.0266 g, 0.19 mmol) in dimethylformamide (DMF, 1.5 mL) and water (1.5 mL) was stirred 
for 15 min under N2 atmosphere. Subsequently, G1-PABA (0.020 g, 0.048 mmol), methoxy-nitro 
phenyl boronic acid (0.0096, 0.057 mmol), triphenylphosphine (0.0015 g, 0.0057 mmol) and Pd(AcO)2 
(0.0004 g, 0.017 mmol) were added. The reaction mixture was heated to 100 °C for 24 h (see Scheme 
2). Once the reaction was complete, it was allowed to cool to room temperature, and the resulting 
mixture was extracted with EtOAc (3 × 25 mL). The organic layer was washed with distilled water 
and brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The obtained 
residue was purified by flash chromatography with a mobile phase consisting of hexane/EtOAc (8:2), 
affording a 13% yield of compound 5 as a gray solid, Rf = 0.5 (hexane/EtOAc 8:2), mp = 200 °C. HPLC 
purity = 87.31 %. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, 1H, J = 7.1 Hz, H-7), 7.68 (s, 1H, H-9), 7.31 (t, 
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3.8.3. Synthesis of (3aS, 4R, 9bR)-4-(6-(3-Methoxyphenyl)benzo[d][1,3]dioxol-5-yl)-
3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-carboxylic acid, 5
Compound 5 was obtained through a Suzuki–Miyaura cross-coupling reaction [63]. A
solution of K2CO3 (0.0266 g, 0.19 mmol) in dimethylformamide (DMF, 1.5 mL) and water
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(1.5 mL) was stirred for 15 min under N2 atmosphere. Subsequently, G1-PABA (0.020 g,
0.048 mmol), methoxy-nitro phenyl boronic acid (0.0096, 0.057 mmol), triphenylphosphine
(0.0015 g, 0.0057 mmol) and Pd(AcO)2 (0.0004 g, 0.017 mmol) were added. The reaction
mixture was heated to 100 ◦C for 24 h (see Scheme 2). Once the reaction was complete, it
was allowed to cool to room temperature, and the resulting mixture was extracted with
EtOAc (3 × 25 mL). The organic layer was washed with distilled water and brine, dried
over anhydrous Na2SO4 and concentrated under reduced pressure. The obtained residue
was purified by flash chromatography with a mobile phase consisting of hexane/EtOAc
(8:2), affording a 13% yield of compound 5 as a gray solid, Rf = 0.5 (hexane/EtOAc 8:2),
mp = 200 ◦C. HPLC purity = 87.31 %. 1H NMR (300 MHz, CDCl3) δ 7.69 (d, 1H, J = 7.1
Hz, H-7), 7.68 (s, 1H, H-9), 7.31 (t, 1H, J = 8.8 Hz, H-5′ ′), 7.18 (s, 1H, H-7′), 6.88 (dd, 1H, J
= 7.9, 2.9 Hz, H-6′ ′), 6.82 (d, 1H, J = 7.6 Hz, H-4′ ′), 6.78 (d, 1H, J = 1.7 Hz, H-2′ ′), 6.71 (s,
1H, H-4′), 6.54 (d, 1H, J = 8.8 Hz, H-6), 6.02 (m, 2H, H-2′), 5.90 (m, 1H, H-1), 5.69 (m, 1H,
H-2), 4.70 (d, 1H, J = 3 Hz, H-4), 3.81 (s, 3H, OMe), 3.81 (dd, 1H, J = 17.6, 8.8 Hz, H-9b), 2.80
(dt, 1H, J = 8.3, 3 Hz, H-3a), 2.64 (dd, J = 15.2, 8.3 Hz, H-3 down), 1.97 (m, 1H, H-3 up).
13C NMR (75 MHz, CDCl3) δ 171.6 (CO2H), 159.3 (C-1′ ′), 150.6 (C-5a), 147.4 (C-3′a), 142.0
(C-7′a), 146.2 (C-1′ ′), 135.1 (C-5′), 132.6 (C-9a), 124.7 (C-6′), 118.8 (C-8), 101.2 (C-2′), 131.8
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31.9 (C-3). HRMS (ESI) calculated for ([C27H23NO5] + H)+: 442.1654; found: 442.1646.
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butoxycarbonyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-carboxylic acid, 7
To a cold solution of G1-PABA in DMF (3.0 mL), triethylamine (336 µL, 2.413 mmol)
was added dropwise and with continuous stirring for 30 min at the same temperature.
Subsequently, di-tert-butyl dicarbonate (Boc2O, 0.5268 g, 2.413 mmol) was added, the
reaction mixture was allowed to reach room temperature and continued overnight with
vigorous stirring (see Scheme 3). The progress of the reaction was monitored by TLC,
and the resulting mixture was extracted with EtOAc (3 × 25 mL). The organic phase
was washed with water and brine, dried over anhydrous Na2SO4 and concentrated to
dryness. The residue obtained was purified by flash chromatography using a mobile phase
of hexane/EtOAc (9:1), affording a 54% yield of compound 7 as a pearl yellow solid, Rf
= 0.63 (hexane/EtOAc 9:1), mp = 184.3 ◦C. HPLC purity = 95.50 %. 1H NMR (300 MHz,
CDCl3) δ 7.88 (d, 1H, J = 1.5 Hz, H-9), 7.81 (dd, 1H, J = 8.4, 1.5 Hz, H-7), 7.61 (d, 1H, J = 8.8
Hz, H-6), 6.94 (s, 1H, H-7′), 6.29 (s, 1H, H-4′), 6.17 (m, 1H, H-1), 6.05 (d, 1H, J = 9.7 Hz, H-4),
5.85 (AB, 2H, H-2′), 5.64 (m, 1H, H-2), 3.85 (bd, 1H, J = 8.4 Hz, H-9b), 3.44 (q, 1H, J = 8.3
Hz, H-3a), 2.20 (dd, 1H, J = 16.3, 8.3 Hz, H-3 down), 1.79 (dd, 1H, J = 6.5, 6.8, Hz, H-3 up),
1.40 (s, 9H, OtBu). 13C NMR (75 MHz, CDCl3) δ 165.6 (CO2H), 153.3 ( -carbamate), 147.0
(C-7′a), 146.9 (C-3′a), 141.4 (C-5a), 134.2 (C-9a), 132.2 (C-5′), 114.4 (C-6′), 81.7 (C-tBu), 129.0
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(C-9), 127.4 (C-7), 124.7 (C-6), 112.3 (C-7′), 107.9 (C-4′), 133.0 (C-1), 56.0 (C-4), 101.6 (C-2′),
131.8 (C-2), 43.5 (C-9b), 41.6 (C-3a), 34.9 (C-3), 28.2 (3Me-tBu). HRMS (ESI) calculated for
[C25H24BrNO6Na] + [M + Na]+: 536.0679; found: 536.0669.
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3.9. Purity Analysis by HPLC
All HPLC analyses were performed using an Agilent 1260 infinity series liquid chro-
matograph (Agilent Technologies, Palo Alto, CA, USA) equipped with a quaternary pump
delivery system (G1311B), robotic autosampler (G1316A), column thermostat (G1316A)
and multiwavelength UV detector (G1315C), and the results were analyzed by OpenLab
CDS EZChrom. The mobile phase with isocratic elution consisted of a mixture of (A) 0.2%
acetic acid in water (v/v) at pH 3.0 and (B) CAN (acetonitrile) in a proportion of 40% A
and 60% B. The system was ready for the next injection without further equilibration. The
mobile phase was prepared fresh daily using deionized water that was filtered (0.22 µm)
and degassed prior to use. The flow rate was 0.5 mL/min. The proposed method utilized a
Zorbax SB-C18 column (5 µm, 4.6 × 150 mm) at a temperature of 25 ◦C. Acceptable purity
was delimited when all compounds were confirmed by ≥95%.
3.10. Cell Culture
Four cell lines were used for this study. The human renal cell carcinoma cell line RCC4
was stably transfected with an empty vector, pcDNA3 (ECACC N-03112702; called RCC4-
VA), which confers neomycin resistance, or with pcDNA3-VHL (ECACC N-0312703; called
RCC4-VHL), which confers neomycin resistance and encodes the VHL tumor suppressor
gene, pVHL, which is associated with resistance to chemotherapy. RCC4 plus the empty
vector served as a negative control cell line to study the effects of pVHL expression by
pcDNA3-VHL. The other two cell lines used in this study were the pancreatic cancer cell line
MIA Paca-2 and the liver cancer cell line Hep G2. Cell culture medium, fetal bovine serum
(FBS), L-glutamine, sodium pyruvate, minimum essential medium (MEM) nonessential
amino acids, penicillin-streptomycin, triple express, phosphate-buffered saline (PBS) and
bovine insulin were purchased from Life Technologies (Gibco, Invitrogen Corporation, CA,
USA). MTT and methyl methanesulfonate (MMS) were purchased from Sigma Chemical Co.
(St. Louis, MO, USA). Cells were maintained and plated with a robotic cell culture system,
SelecT (TAP Biosystems). Hep G2 and MIA Paca-2 cells were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). Hep G2 cells (human liver carcinoma,
CCL-8065) were grown in ATCC-formulated Eagle’s MEM with 10% qualified FBS, 2 mM
L-glutamine, 1 mM sodium pyruvate and 100 µM MEM nonessential amino acids. The MIA
Paca-2 cell line (ATCC CRL-1420), a fibroblast primary pancreatic adenocarcinoma cell
line that contains mutated K-RAS, P16 and P53 genes, was grown in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, 2.5% fetal horse serum, 1%
L-glutamine and 1% penicillin–streptomycin. RCC4-VA and RCC4-VHL cell lines were
maintained in Dulbecco’s modified Eagle’s medium, supplemented with 10% FBS, 0.01%
L-glutamine 200 mM, 0.01% penicillin–streptomycin (GIBCO) and 0.001% Geneticin G418
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0.5 mg/mL (GIBCO). Cell cultures were grown at 37 ◦C in a humidified atmosphere of 5%
CO2 and 95% air.
3.11. Antiproliferative Assays
The rate of MTT reduction is an indicator of the functional integrity of mitochondria
and hence of cellular viability [64,65]. For this assay, cells were treated with compounds
for 72 h. These cells were then seeded into 96-well plates at a density of 103 cells/well for
Hep G2, MIA Paca-2, RCC4-VA and RCC4-VHL. Three microliters of each pure compound
were dispensed into 597 µL of fresh medium (see SM for purity statement). From this
mixture, 200 µL was transferred to three different cell plates with the Biomek FX (Beckman
Coulter) automated liquid handling system. MMS was used as a positive control and
0.5% DMSO was used as a negative control. The maximum concentration of DMSO was
0.5% to minimize any background solvent toxicity. Compounds were tested in triplicate
with 10-point dilutions. After compounds and controls had been added, the plates were
incubated at 37 ◦C in a 5% CO2 incubator for 72 h. After this time, the MTT solution was
prepared at 5 mg/mL in PBS 1× and then diluted to 0.5 mg/mL in MEM without phenol
red. The sample solution in each well was skimmed off, and 100 µL of MTT dye was
added to each well. The plates were gently shaken and incubated for 3 h at 37 ◦C in a 5%
CO2 incubator. The supernatant was removed, and 100 µL of 100% DMSO was added.
The plates were gently shaken to solubilize the formed formazan. The absorbance was
measured using a VictorTM multireader at a wavelength of 570 nm. One-way ANOVA test
was performed to determine any significant difference between each compound treatment
and the DMSO control; p > 0.05 was considered as statistically significant.
4. Conclusions
Bioinformatic tools, such as molecular docking and molecular dynamics simulations,
provide relevant structural information, which allows the characterization of structural
features that carry out molecular recognition. This offers a broad panorama in the design
of selective drugs for the treatment of diseases. Under this context, we designed three
compounds that showed notable inhibitory activity against GPER when tested in noncon-
ventional cell models. According to the chemical data of the structural modifications of
the GPER pharmacophore, we were able to identify the key entities (bromine atom and
NH group of the piperidine ring) that could be functionalized to improve the activity
of the compounds designed to target this receptor. We found a very good correlation of
the in vitro experimental results with the in silico approximations on GPER. Our results
suggest that GPER has the capacity to recognize different structural scaffolds of flat and
aromatic character, specifically ligands with simple chemical modifications that improve
the stereoelectronic properties of the pharmacophore. A comparison of the results obtained
in this study with our previous structural insights demonstrates the great capability of
GPER to bind ligands of different chemical structures, specifically ligands with simple
chemical modifications over their pharmacophores. Nevertheless, additional assays, for
example, binding assays and intracellular Ca2+ mobilization, will be crucial to corroborate
our hypothesis. The appropriate use of rational in silico methods and tools could yield new
compounds for the promising list of ligands to be used as potential drugs in cancer therapy.
Supplementary Materials: The explanation will be as follow: The Supplementary Material for this
paper is available online at https://www.mdpi.com/1424-8247/14/1/49/s1, 1H and 13C NMR
spectra data, HPLC data to corroborate the purity statement, Figure S1. Binding pose yielded by
docking analysis for (A) Compound 4, (B) Compound 5 and (C) Compound 7. H bond interactions
are depicted as red dashes, and Force Field parameters employed in MD and Docking simulations.
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